Investment case
PTC Therapeutics, Inc.
PTCT · 6 developments mapped · last assessed 2026-09-29
Market Ontology has mapped 6 macro, policy, and market developments to PTC Therapeutics, Inc. since 2026-09-14. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for PTCT yet, so no modelled value is shown. The PTCT valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run PTCT on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Main threat
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen
Increased competitive pressure in the Myotonic Dystrophy Type 1 (DM1) treatment landscape, potentially impacting future market share and pricing power for competing therapies.
· Moves market share projections for dm1 therapies, pricing power for dm1 therapies, probability of success for competing dm1 programs
- Open question
uniQure N.V. Reports 48-Month Data for AMT-130 in Huntington’s Disease
Indirect impact on investor sentiment for companies developing treatments for rare neurological disorders, particularly those with gene therapy platforms or similar therapeutic modalities.
· Moves market size and competitive intensity for rare neurological disorders, investor appetite for gene therapy investments, perceived risk/reward of similar development programs
What changed, by assumption
- 2026-09-29Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen
- 2026-09-14FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy
- 2026-09-29uniQure N.V. Reports 48-Month Data for AMT-130 in Huntington’s Disease
- 2026-09-14FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA
- 2026-09-24Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-08-28 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-08-28 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-08-28 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-09-29 | Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen | Bearish | 3-12m | 0.60 |
| 2026-09-29 | uniQure N.V. Reports 48-Month Data for AMT-130 in Huntington’s Disease | mixed | 1-3m | 0.30 |
| 2026-09-24 | Ionis Reports Positive Phase III Endpoints in ALS and Kidney Disease | watch | 3-12m | 0.20 |
| 2026-09-15 | BioMarin Pharmaceutical Inc. Discontinues VOXZOGO Development for Noonan Syndrome | watch | 3-12m | 0.20 |
| 2026-09-14 | FDA Approves Scholar Rock's Isembyld for Spinal Muscular Atrophy | Bearish | 3-12m | 0.40 |
| 2026-09-14 | FDA Approves Scholar Rock's Isembyld as First Muscle-Targeted Therapy for SMA | mixed | 3-12m | 0.30 |